Is PT-141 (Bremelanotide) Legal in Wisconsin?

What PT-141 (Bremelanotide) Is and Why Its Legal Status Matters

PT-141 is the research name for bremelanotide, a synthetic melanocortin receptor agonist that acts on MC3R and MC4R receptors in the central nervous system to increase sexual desire. Unlike PDE5 inhibitors such as sildenafil, bremelanotide does not rely on vascular mechanisms; it targets the brain's sexual arousal circuitry directly. The FDA approved bremelanotide as Vyleesi (AMAG Pharmaceuticals) on June 21, 2019, making it the second drug ever approved for hypoactive sexual desire disorder (HSDD) in premenopausal women [1].

The Distinction Between Approved Drug and Research Peptide

Before approval, bremelanotide circulated widely as a "research peptide" sold in lyophilized powder form by online vendors. That version was never FDA-approved for human use. Post-approval, the legal picture split into two tracks: the approved product Vyleesi, and the still-unapproved compounded or raw-powder form. Wisconsin residents and their clinicians need to understand which track applies to them, because the two carry very different legal and safety profiles.

Why Melanocortin Peptides Attract Regulatory Attention

The FDA's 2023 guidance on difficult-to-compound substances explains that melanocortin peptides, including bremelanotide, raise concerns about systemic exposure variability and blood-pressure effects when compounded outside controlled manufacturing settings [2]. The key Phase 3 RECONNECT trials (combined N=1,267) showed that 18.3% of participants experienced nausea and 40.3% experienced flushing after bremelanotide injection, confirming that dose precision matters significantly [3].

Federal Legal Framework: FDA Approval and Compounding Rules

FDA Approval Status (Vyleesi)

Vyleesi received full New Drug Application (NDA 210557) approval from the FDA on June 21, 2019 [1]. As an approved drug, it may be prescribed by any licensed U.S. Clinician, filled at any licensed U.S. Pharmacy, and dispensed to Wisconsin patients without restriction beyond a valid prescription. Bremelanotide carries no DEA controlled-substance scheduling, so no DEA registration is required to prescribe or dispense it [4].

The 503A and 503B Compounding Problem

The Drug Quality and Security Act (DQSA) of 2013 created two compounding pharmacy categories: 503A (traditional compounding pharmacies filling individual patient prescriptions) and 503B (outsourcing facilities producing larger batches) [5]. Both categories are prohibited from compounding copies of FDA-approved drugs when the compounded version presents no clinical difference, under 21 U.S.C. § 503A(b)(1)(D) and § 503B(a)(5) respectively.

The FDA maintains a list of drug products that present demonstrable difficulties for compounding [6]. Bremelanotide appears on that list as a Category 2 substance, citing concerns about peptide stability, sterility assurance, and blood-pressure variability. Placement on the Category 2 list does not create an absolute criminal ban on compounding overnight, but it signals that FDA enforcement action against pharmacies compounding bremelanotide is likely and that insurers and telehealth platforms typically will not fill such compounds [2].

What "Research Chemical" Sales Mean Legally

Vendors selling raw bremelanotide powder labeled "for research use only, not for human use" are operating in a legal gray zone at the federal level. Under the Federal Analog Act bremelanotide is not a scheduled analogue, so simple possession is not a federal crime [4]. However, selling an unapproved drug intended for human use violates the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. § 331, and the FDA has issued warning letters to peptide vendors [7]. Purchasing from these sources exposes Wisconsin residents to unknown purity, unknown dosing accuracy, and potential FDCA-violation liability if intent to use as a drug can be established.

Wisconsin-Specific Legal Status

No State Scheduling or Ban

Wisconsin's controlled-substance framework is codified at Wisconsin Statutes Chapter 961, which mirrors the federal Controlled Substances Act schedules and adds Wisconsin-specific substances [8]. As of January 2025, bremelanotide appears nowhere in Chapter 961. There is no Wisconsin state statute, Wisconsin Department of Safety and Professional Services (DSPS) rule, or Wisconsin Pharmacy Examining Board regulation that independently bans PT-141 or bremelanotide outside of the federal FDCA framework.

Wisconsin Pharmacy Law and Prescription Requirements

Under Wisconsin Statutes § 450.11, dispensing a prescription drug without a valid prescription is a misdemeanor on the first offense and a felony on subsequent offenses [9]. Bremelanotide is a prescription drug under federal law (21 C.F.R. § 310.3), so the § 450.11 requirement applies directly. A Wisconsin pharmacist filling Vyleesi must have a valid prescription from a Wisconsin-licensed (or telehealth-compliant) prescriber. The Wisconsin Pharmacy Examining Board, operating under DSPS Chapter Phar 7, imposes additional standards for compounding pharmacies, including sterility requirements that track USP <797> standards for sterile preparations [10].

Wisconsin Telehealth Prescribing

Wisconsin codified telehealth prescribing authority at Wisconsin Statutes § 448.9747, permitting a licensed physician or advanced practice clinician to prescribe via synchronous audiovisual telehealth after establishing a valid patient-provider relationship [11]. That means a Wisconsin resident can obtain a Vyleesi prescription through a compliant telehealth platform without an in-person office visit, provided the clinician conducts an adequate history, confirms the HSDD diagnosis (or documents clinical rationale for off-label use), and maintains a medical record. The prescriber must hold a Wisconsin license or qualify under Wisconsin's interstate telehealth provisions.

Clinical Evidence Supporting Bremelanotide Use

The RECONNECT Phase 3 Trials

The key approval data came from two randomized, double-blind, placebo-controlled Phase 3 trials collectively called RECONNECT (combined N=1,267 premenopausal women with HSDD) [3]. Participants self-administered bremelanotide 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated sexual activity, no more than once per 24 hours.

Key findings from the published NEJM report by Simon et al. (2019):

• Statistically significant improvement in the Female Sexual Function Index desire domain vs. Placebo (P<0.001) [3]
• Statistically significant reduction in distress related to low sexual desire on the Female Sexual Distress Scale-Desire/Arousal/Orgasm score vs. Placebo (P<0.001) [3]
• Transient blood pressure decrease of approximately 6 mmHg systolic and 3 mmHg diastolic in the first 12 hours post-dose [3]

The FDA label specifies that Vyleesi should not be used in patients with high cardiovascular risk or uncontrolled hypertension, a restriction that compounded versions without the same quality controls make harder to manage safely [1].

Off-Label Use in Men

No large randomized controlled trial has established bremelanotide as an effective treatment for male sexual dysfunction. A small Phase 2 crossover study by Safarinejad and Hosseini (2008) published in the Journal of Urology (N=60) found that subcutaneous bremelanotide 4 mg improved erectile function scores vs. Placebo (P<0.05), but doses used exceeded the currently approved 1.75 mg dose and the trial predated modern safety data [12]. Clinicians prescribing Vyleesi off-label for men in Wisconsin may do so legally, but should document their clinical rationale and inform patients that evidence remains limited.

Dosing Precision and Why Compounding Concerns Are Real

Bremelanotide's narrow therapeutic window matters. The RECONNECT trials used precisely manufactured 1.75 mg prefilled autoinjectors. A 2021 analysis published in AAPS PharmSciTech found that peptide content in compounded injectable preparations varied by up to 15% from labeled strength across multiple pharmacy batches [13]. A 15% overdose of bremelanotide at 1.75 mg brings the administered dose to approximately 2.01 mg, which sits in a range associated with more frequent nausea and blood-pressure depression in early Phase 1 data [14].

How Wisconsin Residents Can Legally Obtain PT-141 (Bremelanotide)

Step 1: Confirm Clinical Eligibility

The FDA approved Vyleesi specifically for premenopausal women with acquired, generalized HSDD. Clinicians should use validated tools such as the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R) to confirm diagnosis and measure baseline distress before prescribing [15, 16]. A score of 26 or less on the FSFI is the standard threshold for sexual dysfunction in research and clinical settings [15].

Step 2: Choose a Licensed Wisconsin Prescriber

Wisconsin residents have three primary options:

• In-person appointment with a gynecologist, urologist, or sexual health specialist holding a Wisconsin medical license
• Telehealth consultation through a platform compliant with Wisconsin Statutes § 448.9747, using synchronous video [11]
• Primary care clinician familiar with HSDD who is willing to prescribe and monitor

The prescriber should review cardiovascular history, current antihypertensive medications (additive hypotensive effects are possible), and prior treatment with flibanserin (Addyi), the only other FDA-approved HSDD drug, to determine which agent is more appropriate [1].

Step 3: Fill the Prescription at a Licensed Pharmacy

Because compounded bremelanotide sits on the FDA's difficult-to-compound list [6], the standard pathway is filling Vyleesi at a licensed retail or mail-order pharmacy. Vyleesi is available through most major pharmacy benefit managers. As of 2024, the average wholesale price for a single Vyleesi autoinjector is approximately $850; patient assistance programs through the manufacturer (AMAG/Palatin) may reduce out-of-pocket cost significantly [1]. Wisconsin Medicaid's formulary coverage varies by managed care plan; patients should verify prior authorization requirements before the prescription is sent.

Step 4: Administration and Follow-Up

Vyleesi is injected subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity. Patients should remain seated or lying down for 30 minutes after injection to reduce fall risk from transient blood-pressure changes. A follow-up visit at 4 to 8 weeks allows the clinician to assess response using repeat FSFI and FSDS-R scoring and to check for persistent adverse effects [3].

Risks of Obtaining PT-141 Outside the Legal Pathway

Unregulated Online Vendors

Multiple online vendors ship lyophilized bremelanotide powder internationally, including to Wisconsin addresses. These products are not FDA-approved, carry no sterility certification, and have no verified peptide content. The FDA has sent warning letters to domestic peptide suppliers under 21 U.S.C. § 331(d) for selling unapproved new drugs [7]. Receiving these shipments does not automatically constitute a Wisconsin criminal offense (there is no state possession statute for bremelanotide), but self-injecting a non-sterile preparation carries real infection risk, including septicemia from gram-negative contamination.

Compounding Pharmacies Ignoring Category 2 Status

Some compounding pharmacies continue to compound bremelanotide despite its difficult-to-compound listing. A Wisconsin-licensed pharmacist who compounds bremelanotide in a manner that violates USP <797> sterility standards or that constitutes compounding a copy of an approved drug without clinical differentiation may face license discipline from the Wisconsin Pharmacy Examining Board under Wis. Admin. Code § Phar 7.04 [10]. Patients who receive such preparations bear the dosing-accuracy and sterility risks described above.

Clinician Perspective: Prescribing Bremelanotide in Wisconsin

The HealthRX clinical team uses a four-question decision framework before prescribing bremelanotide in any state, including Wisconsin:

1. Has the patient completed a validated HSDD screening tool (FSFI score <26 or FSDS-R score >11)?
2. Are contraindications ruled out (high cardiovascular risk, use of naltrexone, uncontrolled hypertension with systolic blood pressure above 160 mmHg)?
3. Has the patient tried and failed non-pharmacologic therapy (sex therapy, couples counseling) or documented why those options are not appropriate?
4. Is the prescription for FDA-approved Vyleesi dispensed through a licensed pharmacy, rather than a compounded preparation?

If all four criteria are met, a Wisconsin clinician can prescribe bremelanotide with a clear medical record justification and reasonable medicolegal standing. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states: "We recommend treatment with bremelanotide for premenopausal women with HSDD who have documented distress and no cardiovascular contraindications" [17]. That recommendation supports Wisconsin prescribers who follow the approval indication and document appropriately.

The North American Menopause Society (NAMS) 2022 position statement on sexual dysfunction adds that bremelanotide "may be considered when first-line non-pharmacological approaches have been insufficient," reinforcing the place of the drug in a stepwise treatment algorithm [18].

Summary of the Legal Field at a Glance

Wisconsin presents no additional legal barriers to bremelanotide beyond federal law. The drug is not scheduled in Wisconsin, not banned by any Wisconsin pharmacy rule, and fully prescribable by Wisconsin-licensed clinicians. The single most important legal constraint is federal: FDA-approved Vyleesi is the only form of bremelanotide that can be dispensed legally through a standard pharmacy pathway without running into FDCA violations or compounding restrictions. Clinicians who document diagnosis, rule out contraindications, and prescribe Vyleesi through a licensed pharmacy are operating fully within Wisconsin law.

The FDA's 2019 approval letter for bremelanotide remains the definitive federal authorization document [1]. Wisconsin patients who believe they may have HSDD should request an FSFI assessment from their clinician at the first visit.